Clinical Trial Update: TACE Combined With Sorafenib and Tislelizumab for Advanced HCC [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating the combination of TACE with sorafenib and tislelizumab for advanced non-resectable hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Sorafenib (Sorafenib)
• TACE
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Second Affiliated Hospital of Guangzhou Medical University | Conditions: Hepatocellular Carcinoma Non-resectable | Phase 2 | Status: COMPLETED